Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Crecheck vs Crestor in Healthy Adults
NCT06475872Phase 1Completed
- Sponsor
- Hanlim Pharm
- Start
- Nov 2023
- Primary completion
- Dec 2023
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rosuvastatin in hypercholesterolemia and combined hyperlipidemia (2 arms), sponsored by Hanlim Pharm. Primary endpoints: Area under the plasma concentration versus time curve at 48 hours and Peak Plasma Concentration at 48 hours. Started Nov 2023; status: completed.
02
Drugs
rosuvastatin
03
Conditions
hypercholesterolemiacombined hyperlipidemia
Beyond the preview
Go deeper on NCT06475872.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06475872.